RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer

Adam M. Brufsky, Sara Hurvitz, Edith Perez, Raji Swamy, Vicente Valero, Vincent O'Neill, Hope S. Rugo

Research output: Contribution to journalArticlepeer-review

305 Scopus citations

Fingerprint Dive into the research topics of 'RIBBON-2: A randomized, double-blind, placebo-controlled, phase III trial evaluating the efficacy and safety of bevacizumab in combination with chemotherapy for second-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer'. Together they form a unique fingerprint.

Medicine & Life Sciences